Treximet® (sumatriptan and naproxen sodium)

Treximet® (sumatriptan and naproxen sodium) is a selective 5-HT1B/1D receptor agonist (triptan) and antiinflammatory indicated for the acute treatment of migraine, with or without aura, in adults and pediatric patients 12 years of age and older who have a clear migraine diagnosis. It comes in tablet form and is administered by mouth.

Treximet generally begins to work within 2 hours. It is intended to reduce acute migraine symptoms of migraine attackss that have already begun. It should not to be used as a prophylactic therapy to prevent the onset of migraine or to treat hemiplegic or basilar migraine.

Overuse of acute migraine drugs can cause medication overuse headaches. Overuse is considered dosing more than 5 days per month. Symptoms may need to be treated, and detoxification from migraine medications may be required.

What are the ingredients in Treximet?

The active ingredients in Treximet are sumatriptan and naproxen sodium.

How does Treximet work?

Treximet works by binding with 5-HT1B/1D receptors on blood vessels in the brain. It narrows the blood vessels (constriction) surrounding the brain, which is correlated with the relief of migraine. It also reduces the inflammatory substances in the body that can trigger head pain, nausea, sensitivity to light and sound, and other migraine symptoms.

Treximet contains a nonsteroidal anti-inflammatory drug (NSAID), naproxen. NSAIDs inhibit the synthesis of inflammatory mediators. Treximet works best if it is taken as soon as migraine symptoms appear.

What are the possible side effects of Treximet?

Many clinical trials evaluated the safety and efficacy of Treximet. The most common side effects experienced by those taking Treximet include:

  • Dizziness
  • Nausea or dry mouth
  • Pain or tight feeling in your chest, throat, jaw, or neck
  • Fatigue- feeling weak, drowsy, or tired
  • Flushing in pediatric patients (warm, red skin)

Treximet can also cause an increased risk of serious gastrointestinal problems including bleeding, ulceration, and perforation of the stomach or intestines.

This is not an exhaustive list of all potential side effects of Treximet. For more information, consult your doctor or healthcare provider. If you notice any new or worsening side effects when taking Treximet, contact your doctor or healthcare provider immediately.

Things to note about Treximet

Treximet tablets are a fixed combination of sumatriptan and naproxen sodium. Before starting Treximet talk with your doctor if you:

  • Have a history of hypersensitivity to sumatriptan and naproxen sodium
  • Have a history of coronary artery disease (CAD), angina or heart attacks
  • Have a history of high blood pressure or high cholesterol
  • Have a history of hemiplegic or basilar migraine
  • Have a history of stroke, transient ischemic attacks (TIAs)
  • Have a history of Wolff-Parkinson-White syndrome
  • Have a history of peripheral vascular disease (circulation problems)
  • Have a history of ischemic bowel disease
  • Have taken a ergot-containing medication within the 24 hours prior to migraine
  • Have taken an MAO-A inhibitor within 2 weeks prior to migraine onset
  • Take methotrexate, aspirin, furosemide, probenecid, lithium, warfarin, propanalol or other beta blockers
  • Take anti-depressant medicines including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), or tricyclic antidepressants (TCAs)
  • Have severe hepatic (liver) impairment
  • Have severe renal (kidney) problems
  • Are pregnant or planning to get pregnant, Treximet should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.

Before taking Treximet make sure to tell your doctor about all the medicines you take, including prescription and nonprescription, vitamins, and herbal supplements. Treximet and other medicines may affect each other, causing side effects.

Individuals with the above conditions should be monitored closely while taking Treximet.

If there is no response to the first migraine attack treated with Treximet, a physician should reconsider the migraine diagnosis prior to using the medication in any subsequent attacks.

A cardiovascular evaluation should be performed on patients who have never taken a triptan medication but who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) before starting Treximet. For those with a cardiac history, the first dose of Treximet should be administered in a medically supervised setting and an electrocardiogram (ECG) should be performed immediately following the dose.

Dosing Information

Treximet tablets are taken by mouth with water or other liquids. They can be taken with or without food. Tablets should not be split, crushed, or chewed. Treximet comes in 2 strengths, 10/60 mg (sumatriptan and naproxen sodium) and 85/500 mg (sumatriptan and naproxen sodium). Treximet contains a higher amount of sumatriptan than the lowest effective dose.

If only partial migraine relief is attained or symptoms return quickly, adults may take a second dose 2 hours after the first. The maximum adult dose in a 24-hour period is 2 tablets. The maximum recommended dosage for children 12-17 is 85/500 mg in a 24-hour period. Use the lowest effective dosage for the shortest possible duration.

Before taking Treximet make sure to tell your doctor about all the medicines you take, including prescription and nonprescription, vitamins, and herbal supplements. Treximet and other medicines may affect each other, causing side effects. Because Treximet can cause dizziness, weakness, or drowsiness, you should not not drive a car, use machinery, or do anything requiring you to be fully alert when taking this medication. Keep track of when you have migraine attacks and when you take Treximet so you can monitor its effectiveness and communicate with your doctor about how the medication is working for you.

For additional details, read the full prescribing information of Treximet.

Written by: Linda Saxl Minton | Last reviewed: June 2018.
View References